87 related articles for article (PubMed ID: 6645671)
21. [Urinary pyrophosphate and hydroxyproline in bone tumors].
Maeda H
Nihon Seikeigeka Gakkai Zasshi; 1969 Dec; 43(11):1075-85. PubMed ID: 4314548
[No Abstract] [Full Text] [Related]
22. [Study of urinary hydroxyproline in osteopathies].
Kocher P
Pathol Biol; 1966 Nov; 14(21):1020-39. PubMed ID: 5339820
[No Abstract] [Full Text] [Related]
23. [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
Minerva Med; 1980 Sep; 71(31):2215-9. PubMed ID: 7422143
[TBL] [Abstract][Full Text] [Related]
24. Urinary hydroxyproline and prognosis in human breast cancer.
Grant CS; Hoare SA; Millis RR; Hayward JL; Wang DY
Br J Surg; 1984 Feb; 71(2):105-8. PubMed ID: 6692099
[TBL] [Abstract][Full Text] [Related]
25. Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer.
Niell HB; Palmieri GM; Neely CL; McDonald MW
Arch Intern Med; 1981 Oct; 141(11):1471-3. PubMed ID: 7283558
[TBL] [Abstract][Full Text] [Related]
26. Urinary hydroxyproline excretion in orthopedic disease, with special reference to systemic bone disease and bone tumor (secondary report).
Nakagawa M; Sugiura Y; Oshima T; Kajino G; Hirako H
Nagoya J Med Sci; 1967 Mar; 29(4):345-67. PubMed ID: 6066099
[No Abstract] [Full Text] [Related]
27. Use of urinary hydroxyproline excretion as a tumor marker in diagnosis and follow-up of prostatic carcinoma.
Unni Mooppan MM; Kim H; Wang JC; Tobin MS; Wax SH
Prostate; 1983; 4(4):397-405. PubMed ID: 6191318
[TBL] [Abstract][Full Text] [Related]
28. [Urinary hydroxyproline excretion in generalized bone diseases].
Czitober H; Raab W
Wien Z Inn Med; 1967; 48(10):401-8. PubMed ID: 5620579
[No Abstract] [Full Text] [Related]
29. [Creatinine-hydroxyproline index in healthy subjects, in hyperthyroidism and in bone neoplasms].
Radom S; Sienczewska-Burzyńska J; Jaruga-Dolińska E; Zulawski M
Pol Arch Med Wewn; 1971 Sep; 47(3):257-64. PubMed ID: 5171080
[No Abstract] [Full Text] [Related]
30. The postabsorptive hydroxyproline in the long-term evaluation of patients with breast cancer.
Niell HB; Neely CL; Palmieri GM; McDonald MW
Cancer; 1983 Oct; 52(8):1442-7. PubMed ID: 6616407
[TBL] [Abstract][Full Text] [Related]
31. [Hydroxyproline in generalized bone diseases].
Czitober H; Raab W
Dtsch Med J; 1970 Jun; 21(12):857-64. PubMed ID: 5512354
[No Abstract] [Full Text] [Related]
32. The hypronosticon test in breast cancer.
Roberts JG; Williams M; Henk JM; Bligh AS; Baum M
Clin Oncol; 1975 Mar; 1(1):33-43. PubMed ID: 1204270
[No Abstract] [Full Text] [Related]
33. Urinary hydroxyproline, serum alkaline phosphatase, calcium and phosphorus in patients with bone neoplasms.
Radom S; Zulawski M; Golebiowska D
Pol Med J; 1972; 11(4):809-14. PubMed ID: 4342776
[No Abstract] [Full Text] [Related]
34. Three-centre study on urinary hydroxyproline excretion in cancer of the breast.
Cuschieri A; Jarvie R; Taylor WH; Cant E; Furnival CM; Blumgart LH
Br J Cancer; 1978 Jun; 37(6):1002-5. PubMed ID: 678421
[TBL] [Abstract][Full Text] [Related]
35. [Hydroxyproline excretion as an index for the evaluation of metabolic bone changes].
Mühlbach R
Beitr Orthop Traumatol; 1966 Oct; 13(10):606-8. PubMed ID: 5977397
[No Abstract] [Full Text] [Related]
36. Circadian rhythm of total urinary hydroxyproline excretion and 3-H hydroxyproline test.
Radom S; Zulawski M; Dahlig E
Clin Chim Acta; 1972 Jun; 39(1):277-8. PubMed ID: 4556834
[No Abstract] [Full Text] [Related]
37. [Determination of serum proline iminopeptidase activity using a fluorescent substrate in patients with Paget's disease and prostatic bone metastases. Preliminary results].
Bouvier M; Colson F; Tebib J; Mathieu M; Vianey-Liaud C
Pathol Biol (Paris); 1986 Apr; 34(4):235-9. PubMed ID: 3528996
[TBL] [Abstract][Full Text] [Related]
38. [Investigation on urinary hydroxyproline--influence of skin collagen on urinary hydroxyproline and its adjustment by hydroxyproline--creatinine ratio].
Yamada Y
Nihon Seikeigeka Gakkai Zasshi; 1970 Aug; 44(8):601-12. PubMed ID: 5530072
[No Abstract] [Full Text] [Related]
39. [Hydroxyproline excretion in the urine in destructive bone processes].
Raab W; Schwägerl W
Wien Klin Wochenschr; 1967 Jan; 79(2):32-5. PubMed ID: 6031951
[No Abstract] [Full Text] [Related]
40. Urinary hydroxyproline levels in patients with prostatic carcinoma.
Erol D; Adalar N; Güvençli S; Simşek F
Int Urol Nephrol; 1983; 15(3):267-70. PubMed ID: 6654633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
